The global epigenetics market is expected to reach USD 16.31
billion by 2022, according to a new report by Grand View Research, Inc. Growing
worldwide prevalence of cancer and other diseases with epigenetic modification
base is expected to drive market growth during the forecast period.
Diagnostic companies are coming up with new products such
as antibodies specific for the detection of modifications and new upgraded kits
for easy and efficient detection of biomarkers. This is expected to attract
pharmaceutical companies to collaborate for the development of therapeutic
drugs.
Presence of pipeline drugs and their expected commercialization
is anticipated to boost penetration rates over the forecast period. For
instance, Ramucirumab (Cyramza) by Eli Lilly and Company was approved by the
FDA for use in combination with Folfiri for the treatment of patients with
metastatic colorectal cancer.
Technology advancements in the field of epigenetics
especially pertaining to the detection of methylation markers related to cancer
development is expected to improve usage rates during the forecast period. For
instance, Epi proLung BL Reflex Assay by Epigenomics helps in the diagnosis of
lung cancer by determining methylation of SHOX2 biomarker gene.
Browse full report by Grand View Research : http://www.grandviewresearch.com/industry-analysis/epigenetics-market
Further key findings from the report suggest:
·
Epigenetic reagents was the
largest market valued at over USD 1.2 billion in 2014 owing to the increasing
amount of R&D investments and high consumption rates. Kits are expected to
gain rapid growth in demand due to the increasing need of rapid and accurate
detection techniques.
·
DNA methylation was the largest
technology segment accounting for over 47.0% revenue in 2014. The introduction
of technological advancement such as Methylation Sensitive PCR (MSP) and rapid
adoption of these products to improve diagnostics efficiency are some factors
attributing for its largest share.
·
Oncology was the largest
application market, with revenue valued at over USD 2.75 billion. Growing
prevalence of cancer with epigenetic modification base and strong product
pipeline are some factors attributing to its market position.
·
Non oncology segment is
anticipated to register the fastest growth of over 20.0% during the forecast
period. The segment is dominated by metabolic diseases owing to, the growing
base of population suffering from diabetes and organ failure and increasing
prevalence of sedentary lifestyle.
·
North America was observed to be
the largest regional epigenetics market accounting for over 38.0% of the
overall revenue, due to factors such as the increasing cancer prevalence,
increasing amount of funding for R&D, growing collaborations between large
pharmaceutical firms for development of improved therapeutics, high patient
awareness levels.
·
The Asia Pacific market is
estimated to witness lucrative growth over the forecast period owing to, the presence
of large prevalence of target diseases and high unmet medical needs
·
Some key players of the
epigenetics market include Illumina, Abcam, Diagenode, Thermo Fisher
Scientific, Merck, Zymo research, Qiagen, CellCentric Ltd, Chroma Therapeutics
Ltd, Eisai Co. Ltd, Novartis International AG, Oncolys Biopharma Inc., Syndax
Pharmaceuticals, Inc., Valirx Plc and Sigma-Aldrich Corporation.
·
Extensive R&D initiatives
aimed at the development of novel drugs and the presence of strong product
pipeline is expected to further boost market growth over the forecast
period.
Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/medical-devices
Grand View Research has
segmented the global epigenetics market on the basis of product, technology,
application and region:
Epigenetics
Product Outlook (Revenue, USD Million, 2015 – 2022)
·
Reagents
·
Kits
·
Instruments
·
Enzymes
·
Services
Epigenetics
Technology Outlook (Revenue, USD Million, 2015 – 2022)
·
DNA Methylation
·
Histone Methylation
·
Histone Acetylation
·
Large noncoding RNA
·
MicroRNA Modification
·
Chromatin structures
Epigenetics
Application Outlook (Revenue, USD Million, 2015 – 2022)
·
Oncology
o Solid
Tumors
o Liquid
Tumors
·
Non Oncology
o Inflammatory
Diseases
o Metabolic
Diseases
o Infectious
Diseases
o Cardiovascular
Diseases
Epigenetics
Market Regional Outlook(Revenue, USD Million, 2015 – 2022)
o North
America
o U.S.
o Canada
o Europe
o UK
o Germany
o Asia
Pacific
o Japan
o China
o India
o Latin
America
o Brazil
o Mexico
o Middle
East and Africa (MEA)
o South
Africa
View Press Release of this research
report by Grand View Research: http://www.grandviewresearch.com/press-release/global-epigenetics-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For More Information: www.grandviewresearch.com
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For More Information: www.grandviewresearch.com
No comments:
Post a Comment